好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

2011 Annual Meeting | Neuro-oncology: Primary Brain Tumors

Sunday 04/10/11
09:00 AM - 01:00 PM Add To Calendar
This program will be presented both in-person and online
This program is not expected to be available in the meeting's On Demand product.
AM Half-Day Course
Jaishri Blakeley, MD, FAAN
Participants should be familiar with the current recommendations for the diagnosis and treatment of primary brain tumors in adults. This includes identifying most appropriate diagnostic techniques, incorporating prognostic and predictive factors into treatment decisions, and current recommendations for systemic therapies. Participants should gain an evidence base for the management of seizures, venous thrombosis, infection during brain tumor treatment, and learn strategies to enhance quality of life for patients with long-term complications and unusual sequelae of tumor therapy.
No CME available
Patient Care & Procedural Skills, Interpersonal and Communication Skills, Professionalism, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice
Trainee, General Neurologist, Specialist Neurologist, Non-neurologist
Case-based, Didactic, Interactive
Event Timeline
09:00 AM - 10:00 AM When Benign is Not Benign: Neuro-oncologic Tumor Syndromes
Scott R. Plotkin, MD, PhD, FAAN
10:05 AM - 11:10 AM Advances, Current and Future, for Treating Malignant Gliomas
Steven S. Rosenfeld, MD, PhD, William A. Weiss, MD, PhD
11:10 AM - 11:25 AM Break
11:30 AM - 12:30 PM Neurologic Management of Patients with Brain Tumors: How Neurologists Can Make the Best of Tough Situations
Jaishri Blakeley, MD, FAAN
12:30 PM - 01:00 PM Questions and Answers
Faculty Disclosures
Jaishri Blakeley, MD, FAAN Dr. Blakeley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Springworks Therapeutics.
Steven S. Rosenfeld, MD, PhD No disclosure on file
Scott R. Plotkin, MD, PhD, FAAN Dr. Plotkin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for NFlection Therapeutics. Dr. Plotkin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Akouos. Dr. Plotkin has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SonALAsense. Dr. Plotkin has stock in NFlection Therapeutics. Dr. Plotkin has stock in NF2 Therapeutics. Dr. Plotkin has stock in SonALAsense. Dr. Plotkin has received research support from Children's Tumor Foundation. Dr. Plotkin has received research support from Department of Defense. Dr. Plotkin has received research support from National Institutes of Health. Dr. Plotkin has received intellectual property interests from a discovery or technology relating to health care.
William A. Weiss, MD, PhD Dr. Weiss has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AACR. Dr. Weiss has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for law firms. Dr. Weiss has stock in StemSynergy Therapeutics. Dr. Weiss has stock in Granule Therapeutics. The institution of Dr. Weiss has received research support from NIH, Alex's Lemonade Stand, Cancer Research UK, Jobie and Panattoni Families, and the Samuel Waxman Cancer Research Foundation .